{"product_id":"omega-3-fish-oil-added-to-statins-a-double-blind-trial-shows-significant-benefits-for-patients-with-residual-high-triglycerides","title":"Omega-3 Fish Oil Added to Statins: A Double-Blind Trial Shows Significant Benefits for Patients with Residual High Triglycerides","description":"\u003cp\u003eThis randomized, double-blind clinical trial investigated whether adding omega-3 fatty acids (OM3-FAs) to statin therapy helps patients who still have high triglycerides (blood fats) despite achieving good LDL (\"bad\") cholesterol control. The study, conducted at 36 medical centers across Korea, found that after 8 weeks of treatment, patients taking 4,000 mg of omega-3 fatty acids plus 20 mg of atorvastatin experienced a 29.8% reduction in triglycerides compared to a 3.6% increase in the statin-only group—a highly significant difference. The combination therapy also significantly improved non-HDL cholesterol, total cholesterol, and other lipid measures, while showing no increase in side effects.\u003c\/p\u003e\n\n\u003ch1\u003eOmega-3 Fish Oil Added to Statins: A Double-Blind Trial Shows Significant Benefits for Patients with Residual High Triglycerides\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#participants\"\u003eWho Was in the Study?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eWhat Treatments Did Patients Receive?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#primary\"\u003eKey Findings: Triglyceride and Non-HDL-C Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#secondary\"\u003eOther Lipid Results: Additional Improvements\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety Results: Side Effects Were Comparable\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Trial Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a randomized, double-blind trial of 200 adults in Korea, adding 4,000 mg of omega-3 fatty acids to 20 mg of atorvastatin for 8 weeks reduced triglycerides by 29.8%.\u003c\/li\u003e\n\u003cli\u003eThe statin-only group's triglycerides rose 3.6% over the same period, a highly statistically significant difference between groups.\u003c\/li\u003e\n\u003cli\u003eAfter 8 weeks, 62.9% of the combination group reached triglycerides below 200 mg\/dL, versus 22.3% of the statin-only group.\u003c\/li\u003e\n\u003cli\u003eAdverse events did not differ between groups, and LDL cholesterol changes were not significantly different, suggesting no interference with statin benefits.\u003c\/li\u003e\n\u003cli\u003eThe trial was short, measured lipid levels rather than heart attacks or strokes, and enrolled mainly Korean adults with diabetes and hypertension.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eFor decades, doctors have focused on lowering low-density lipoprotein cholesterol (LDL-C)—commonly known as \"bad\" cholesterol—to prevent cardiovascular disease. Statins are the most effective and proven medications for this purpose, and they have saved countless lives by reducing heart attacks and strokes.\u003c\/p\u003e\n\n\u003cp\u003eHowever, a critical problem remains: even patients who achieve excellent LDL-C control with intensive statin therapy still face a significant residual risk of cardiovascular events. In other words, getting the \"bad\" cholesterol to optimal levels does not eliminate the risk entirely. This has led researchers to look beyond LDL-C for additional therapeutic targets.\u003c\/p\u003e\n\n\u003cp\u003eOne such target is triglycerides (TG)—a type of fat found in the blood that the body uses for energy. Elevated triglyceride levels, a condition called hypertriglyceridemia, have recently emerged as a reliable and modifiable cardiovascular risk factor. This is especially relevant in Korea, where the prevalence of hypertriglyceridemia is actually \u003cstrong\u003egreater than that of hypercholesterolemia\u003c\/strong\u003e (high cholesterol).\u003c\/p\u003e\n\n\u003cp\u003eRecent scientific evidence supports an independent association between triglyceride level and cardiovascular disease, even after adjusting for conventional risk factors and high-density lipoprotein cholesterol (HDL-C, the \"good\" cholesterol). One study cited in the paper found that elevated triglyceride levels over a 5-year period increased the incidence of coronary heart disease (CHD), regardless of baseline triglyceride level. In another study involving hospitalized patients with acute coronary syndrome (a sudden reduction of blood flow to the heart), those with triglyceride levels above 150 mg\/dL and LDL-C levels below 70 mg\/dL exhibited a \u003cstrong\u003e15% higher coronary heart disease event rate\u003c\/strong\u003e than those with low triglycerides and high LDL-C.\u003c\/p\u003e\n\n\u003cp\u003eParticularly in patients with type 2 diabetes mellitus, two large trials demonstrated that combining statins with triglyceride-lowering medications reduced cardiovascular events in a subgroup of subjects with marked hypertriglyceridemia and low HDL-C levels. For this reason, recent guidelines have emphasized the importance of \u003cstrong\u003enon-HDL-C (non-high-density lipoprotein cholesterol)\u003c\/strong\u003e as a secondary treatment target for preventing cardiovascular disease in patients with mixed dyslipidemia (abnormal levels of multiple blood fats) who have already achieved their LDL-C target.\u003c\/p\u003e\n\n\u003cp\u003eAmong the various options for controlling hypertriglyceridemia, omega-3 fatty acids (OM3-FAs)—commonly known as fish oil—have shown impressive results. Previous research demonstrated that OM3-FAs induced a greater reduction of triglycerides and were associated with few adverse effects when added to statins. This phase III study was designed to rigorously test whether adding OM3-FAs to atorvastatin could improve outcomes in patients who still had high triglycerides despite statin treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis was a \u003cstrong\u003erandomized, double-blind, placebo-controlled, parallel-group, phase III multicenter study\u003c\/strong\u003e. Let's break down what each of these terms means:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRandomized:\u003c\/strong\u003e Patients were assigned to treatment groups by chance, like flipping a coin, to ensure fair comparison.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDouble-blind:\u003c\/strong\u003e Neither the patients nor the doctors knew who was receiving the active treatment versus the placebo. This prevents bias.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlacebo-controlled:\u003c\/strong\u003e One group received a dummy pill (placebo) so researchers could compare the real effect of the medication.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParallel-group:\u003c\/strong\u003e Each group received one treatment throughout the study; no crossover.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhase III:\u003c\/strong\u003e A late-stage clinical trial that tests efficacy and safety in a larger group of patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe study was conducted at \u003cstrong\u003e36 centers throughout Korea\u003c\/strong\u003e between \u003cstrong\u003eMay 4, 2016 and May 16, 2017\u003c\/strong\u003e. Adult subjects aged 20 to 79 years with high cardiovascular disease risk, according to the Korean dyslipidemia guideline, were screened at their first visit.\u003c\/p\u003e\n\n\u003cp\u003eThe trial consisted of two main phases: a 4-week run-in period and an 8-week treatment period. During the run-in period, all patients received open-label (unblinded) atorvastatin 20 mg\/day to establish a stable baseline. Patients who were already taking 20 mg\/day of atorvastatin for at least 4 weeks could skip the run-in period and proceed directly to the second screening.\u003c\/p\u003e\n\n\u003cp\u003eTo be eligible for the study, participants had to meet specific criteria at their initial screening:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eFor those not taking statins for the last 4 weeks: fasting triglyceride levels ≥300 mg\/dL with LDL-C levels between 100 and 160 mg\/dL.\u003c\/li\u003e\n  \u003cli\u003eFor those already taking statins for the last 4 weeks: fasting triglyceride levels ≥200 mg\/dL and \u0026lt;500 mg\/dL with LDL-C levels \u0026lt;110 mg\/dL.\u003c\/li\u003e\n  \u003cli\u003eNon-smoking during the study period.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eAt the second screening (after the run-in period or directly for those already on atorvastatin), subjects needed to meet all of the following criteria:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eResidual hypertriglyceridemia with fasting triglyceride levels ≥200 mg\/dL and \u0026lt;500 mg\/dL, with LDL-C levels \u0026lt;110 mg\/dL.\u003c\/li\u003e\n  \u003cli\u003eDecreased LDL-C during the run-in period compared to the first screening (for those not previously taking statins).\u003c\/li\u003e\n  \u003cli\u003eAn adherence rate of at least 80% for statin use during the run-in period.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eAll participants received dietary counseling for dyslipidemia based on the Korean dyslipidemia guideline during their screening visits. The researchers applied a comprehensive list of exclusion criteria to ensure patient safety, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eHistory of unstable angina, acute myocardial infarction (heart attack), coronary artery revascularization, or transient ischemic attack or stroke within 3 months prior to screening.\u003c\/li\u003e\n  \u003cli\u003eHistory of surgery for aortic aneurysm within 6 months prior to screening.\u003c\/li\u003e\n  \u003cli\u003eUnexplained muscle pain (myalgia) or a diagnosis of myalgia or rhabdomyolysis (a severe muscle breakdown condition) at screening.\u003c\/li\u003e\n  \u003cli\u003eHistory of pancreatitis (inflammation of the pancreas) prior to screening.\u003c\/li\u003e\n  \u003cli\u003eSignificant comorbid medical illness in cardiovascular, hepatobiliary (liver\/bile), neuropsychiatric, or endocrine systems.\u003c\/li\u003e\n  \u003cli\u003ePositive HIV test result.\u003c\/li\u003e\n  \u003cli\u003eHistory of malignant tumor within 2 years, except for completely resolved basal cell or squamous cell carcinoma.\u003c\/li\u003e\n  \u003cli\u003eUse of prohibited concomitant medications.\u003c\/li\u003e\n  \u003cli\u003eSex hormone replacement or oral contraceptive use within 2 months prior to screening.\u003c\/li\u003e\n  \u003cli\u003eUncontrolled hypertension (systolic blood pressure ≥180 mm Hg and\/or diastolic blood pressure ≥110 mm Hg).\u003c\/li\u003e\n  \u003cli\u003eSerum creatinine levels ≥2 times the upper limit of normal.\u003c\/li\u003e\n  \u003cli\u003eLiver enzyme (ALT and\/or AST) levels ≥3 times the upper limit of normal.\u003c\/li\u003e\n  \u003cli\u003eCreatine phosphokinase levels five times the upper limit of normal.\u003c\/li\u003e\n  \u003cli\u003eCertain genetic disorders, including galactose intolerance, Lapp lactase deficiency, or galactose malabsorption.\u003c\/li\u003e\n  \u003cli\u003eAllergy or hypersensitivity to study medications.\u003c\/li\u003e\n  \u003cli\u003eDrug or alcohol abuse within 2 years prior to screening.\u003c\/li\u003e\n  \u003cli\u003ePregnancy, breast-feeding, or plans to become pregnant during the trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"participants\"\u003eWho Was in the Study?\u003c\/h2\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e558 subjects were screened\u003c\/strong\u003e for the study. Of these, \u003cstrong\u003e268 subjects entered the run-in period\u003c\/strong\u003e, and \u003cstrong\u003e215 subjects were randomly assigned\u003c\/strong\u003e to one of the two treatment groups: 105 subjects to the ATOMEGA group and 110 subjects to the atorvastatin group.\u003c\/p\u003e\n\n\u003cp\u003eFrom the randomized population, 8 subjects in the ATOMEGA group and 7 subjects in the atorvastatin group were excluded from the safety analysis due to violation of eligibility criteria or incomplete measurement of triglycerides or non-HDL-C levels. This left \u003cstrong\u003e200 subjects (97 in the ATOMEGA group and 103 in the atorvastatin group)\u003c\/strong\u003e in the full analysis set for evaluating efficacy.\u003c\/p\u003e\n\n\u003cp\u003eAt baseline, the two groups were very well matched. Here are the key characteristics of the study participants:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMean age:\u003c\/strong\u003e 58.3 years (ATOMEGA group: 58.7 ± 10.1 years; atorvastatin group: 58.0 ± 11.4 years)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMale sex:\u003c\/strong\u003e 66.0% in the ATOMEGA group vs. 63.1% in the atorvastatin group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBody mass index (BMI):\u003c\/strong\u003e 27.3 ± 3.5 kg\/m² vs. 27.0 ± 3.4 kg\/m² (both groups were in the overweight\/obese range)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevalence of hypertension:\u003c\/strong\u003e 82.5% vs. 81.6%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevalence of diabetes:\u003c\/strong\u003e 89.7% vs. 86.4% (P=0.478)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFasting plasma glucose:\u003c\/strong\u003e 141.1 ± 53.0 mg\/dL vs. 132.3 ± 36.9 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGlycosylated hemoglobin (HbA1c):\u003c\/strong\u003e 7.4% ± 1.3% vs. 7.2% ± 1.2%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10-year coronary heart disease risk score:\u003c\/strong\u003e 10.3% ± 7.2% vs. 8.7% ± 7.1%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevious use of statins:\u003c\/strong\u003e 97.9% vs. 96.1%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBaseline lipid profiles were also similar between groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTriglycerides:\u003c\/strong\u003e 298.5 ± 71.2 mg\/dL vs. 293.0 ± 75.7 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-HDL-C:\u003c\/strong\u003e 116.1 ± 21.7 mg\/dL vs. 111.6 ± 19.7 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTotal cholesterol (TC):\u003c\/strong\u003e 153.5 ± 22.6 mg\/dL vs. 151.0 ± 21.6 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLDL-C:\u003c\/strong\u003e 77.1 ± 20.1 mg\/dL vs. 75.7 ± 18.7 mg\/dL\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHDL-C:\u003c\/strong\u003e 37.4 ± 8.6 mg\/dL vs. 39.4 ± 8.9 mg\/dL\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNo significant differences in any variable were found between the two groups, confirming that randomization successfully created comparable groups—a key requirement for a reliable clinical trial.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eWhat Treatments Did Patients Receive?\u003c\/h2\u003e\n\n\u003cp\u003eEligible subjects were randomly assigned in a 1:1 ratio to one of two groups for 8 weeks:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eATOMEGA group:\u003c\/strong\u003e Patients received four capsules of ATOMEGA, each containing omega-3 fatty acids 1,000 mg plus atorvastatin calcium 5 mg, and one tablet of placebo (dummy) atorvastatin 20 mg. This means the total daily dose was \u003cstrong\u003e4,000 mg of omega-3 fatty acids plus 20 mg of atorvastatin\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAtorvastatin group:\u003c\/strong\u003e Patients received four capsules of placebo containing \u003cstrong\u003eolive oil 1,000 mg each\u003c\/strong\u003e (to mimic the appearance and feel of the fish oil capsules) and one tablet of atorvastatin calcium 20 mg. This was the standard statin-only therapy.\u003c\/p\u003e\n\n\u003cp\u003eThe use of olive oil as a placebo is worth noting. Olive oil contains monounsaturated fats but not the active omega-3 fatty acids (EPA and DHA) found in fish oil, making it an appropriate control that maintains blinding.\u003c\/p\u003e\n\n\u003ch2 id=\"primary\"\u003eKey Findings: Triglyceride and Non-HDL-C Results\u003c\/h2\u003e\n\n\u003cp\u003eThe primary efficacy endpoints of the study were the \u003cstrong\u003epercentage changes in triglyceride (TG) and non-HDL-C levels from baseline after 8 weeks of treatment\u003c\/strong\u003e. The results were striking.\u003c\/p\u003e\n\n\u003ch3\u003eTriglyceride Reduction\u003c\/h3\u003e\n\n\u003cp\u003eThe ATOMEGA group achieved a dramatic reduction in triglyceride levels:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eATOMEGA group:\u003c\/strong\u003e Triglycerides fell from 298.5 ± 71.2 mg\/dL at baseline to 210.6 ± 117.1 mg\/dL, a mean percent change of \u003cstrong\u003e–29.8%\u003c\/strong\u003e (P\u0026lt;0.001 compared to baseline).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtorvastatin group:\u003c\/strong\u003e Triglycerides actually rose slightly from 293.0 ± 75.7 mg\/dL to 299.3 ± 133.9 mg\/dL, a mean percent change of \u003cstrong\u003e+3.6%\u003c\/strong\u003e (P=0.593, not significant).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe difference between the two groups was \u003cstrong\u003ehighly statistically significant (P\u0026lt;0.001)\u003c\/strong\u003e. In plain terms, this means there is less than a 0.1% probability that this difference occurred by random chance.\u003c\/p\u003e\n\n\u003ch3\u003eNon-HDL-C Reduction\u003c\/h3\u003e\n\n\u003cp\u003eNon-HDL-C (calculated as total cholesterol minus HDL-C) is a secondary target recommended by recent guidelines because it encompasses all \"bad\" cholesterol particles, including LDL and VLDL:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eATOMEGA group:\u003c\/strong\u003e Non-HDL-C fell from 116.1 ± 21.7 mg\/dL to 103.6 ± 28.6 mg\/dL, a mean percent change of \u003cstrong\u003e–10.1%\u003c\/strong\u003e (P\u0026lt;0.001).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtorvastatin group:\u003c\/strong\u003e Non-HDL-C increased from 111.6 ± 19.7 mg\/dL to 115.8 ± 28.6 mg\/dL, a mean percent change of \u003cstrong\u003e+4.9%\u003c\/strong\u003e (P=0.095, not significant).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAgain, the difference between groups was \u003cstrong\u003ehighly statistically significant (P\u0026lt;0.001)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eReaching Treatment Targets\u003c\/h3\u003e\n\n\u003cp\u003ePerhaps the most clinically meaningful finding was the proportion of patients who successfully reached the triglyceride treatment target of \u003cstrong\u003ebelow 200 mg\/dL\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eATOMEGA group:\u003c\/strong\u003e \u003cstrong\u003e62.9%\u003c\/strong\u003e of patients reached the target.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtorvastatin group:\u003c\/strong\u003e Only \u003cstrong\u003e22.3%\u003c\/strong\u003e of patients reached the target.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis difference was highly significant (P\u0026lt;0.001) and demonstrates that adding omega-3 fatty acids to statin therapy nearly tripled the likelihood of achieving optimal triglyceride control.\u003c\/p\u003e\n\n\u003ch2 id=\"secondary\"\u003eOther Lipid Results: Additional Improvements\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers also measured several secondary lipid parameters to understand the full effect of the combination therapy. The ATOMEGA group showed significant improvements in multiple lipid measures compared to the atorvastatin-only group:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTotal cholesterol (TC):\u003c\/strong\u003e The ATOMEGA group experienced a –6.1% change from baseline, compared to +3.8% in the atorvastatin group (P\u0026lt;0.001 between groups).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVLDL-C (very low-density lipoprotein cholesterol):\u003c\/strong\u003e The ATOMEGA group saw a –30.1% change, while the atorvastatin group had +4.9% (P\u0026lt;0.001). VLDL-C carries triglycerides in the blood, so this large reduction aligns with the triglyceride findings.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApolipoprotein A1 (Apo A1):\u003c\/strong\u003e The ATOMEGA group had a –3.2% change vs. +1.0% in the atorvastatin group (P=0.016). Apo A1 is the main protein in HDL (\"good\") cholesterol.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApolipoprotein B (Apo B):\u003c\/strong\u003e The ATOMEGA group showed –3.1% vs. +3.0% in the atorvastatin group (P=0.033). Apo B is the main protein in \"bad\" cholesterol particles, so a reduction is beneficial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHDL-C:\u003c\/strong\u003e The ATOMEGA group showed a +6.4% increase vs. +2.6% in the atorvastatin group. While the increase within the ATOMEGA group was significant (P=0.003), the difference between groups did not reach statistical significance (P=0.096).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLDL-C:\u003c\/strong\u003e The ATOMEGA group showed –1.9% vs. +6.5% in the atorvastatin group. The difference between groups was \u003cstrong\u003enot statistically significant (P=0.226)\u003c\/strong\u003e, meaning the combination therapy did not meaningfully change LDL-C beyond statin alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe fact that LDL-C was not significantly different between groups is actually an expected and reassuring finding—it shows that adding omega-3 fatty acids does not interfere with the cholesterol-lowering benefits of atorvastatin, while providing additional improvements in other important lipid measures.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety Results: Side Effects Were Comparable\u003c\/h2\u003e\n\n\u003cp\u003eSafety is always a critical concern when adding a new medication to an existing treatment regimen. The researchers carefully monitored adverse events (AEs) throughout the study, including laboratory parameters, electrocardiograms, vital signs, and physical examinations.\u003c\/p\u003e\n\n\u003cp\u003eThe key safety finding is reassuring: \u003cstrong\u003ethe incidence of adverse events did not differ between the two groups\u003c\/strong\u003e. In other words, adding omega-3 fatty acids to atorvastatin did not increase the risk of side effects compared to atorvastatin alone.\u003c\/p\u003e\n\n\u003cp\u003eThis finding is consistent with the well-established safety profile of omega-3 fatty acids. Previous studies have shown that OM3-FAs are associated with few adverse effects when added to statins, making them an attractive option for patients with residual hypertriglyceridemia.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe results of this clinical trial have important implications for the management of patients with residual hypertriglyceridemia who are already being treated with statins. Here's what the findings mean in practical terms:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, the study confirms that statin monotherapy is often insufficient for controlling triglycerides.\u003c\/strong\u003e In the atorvastatin-only group, triglycerides actually increased slightly over 8 weeks. Many patients with high cardiovascular risk—especially those with diabetes—continue to have elevated triglycerides despite optimal statin therapy, leaving them with residual cardiovascular risk.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the combination of omega-3 fatty acids and atorvastatin provides meaningful improvements within just 8 weeks.\u003c\/strong\u003e The near-30% reduction in triglycerides and the 10% reduction in non-HDL-C represent clinically valuable improvements in a patient population that has already achieved their primary LDL-C goal. Importantly, the significant reduction in non-HDL-C addresses the guideline-recommended secondary target for preventing cardiovascular events.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, the high rate of achieving the triglyceride target (\u0026lt;200 mg\/dL) is especially notable.\u003c\/strong\u003e In the ATOMEGA group, 62.9% of patients reached this goal compared to only 22.3% in the atorvastatin group. For patients at high cardiovascular risk, reaching this target could potentially translate into fewer future cardiovascular events, although this study was not designed to measure long-term cardiovascular outcomes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, the safety profile is favorable.\u003c\/strong\u003e The fact that adverse events were comparable between the two groups suggests that this combination can be added to clinical practice without concerns about additional side effects. This is particularly important for patients with diabetes, who made up the vast majority of the study population (approximately 87–90%) and who often face polypharmacy (taking multiple medications).\u003c\/p\u003e\n\n\u003cp\u003eIt is also worth noting that the study population had a very high prevalence of diabetes and hypertension, along with a mean 10-year coronary heart disease risk score of approximately 9.9%. These are patients who need aggressive management of all cardiovascular risk factors, and the addition of omega-3 fatty acids to their statin therapy offers a well-tolerated strategy to further optimize their lipid profile.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Trial Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eWhile this study provides strong evidence for the benefits of adding omega-3 fatty acids to atorvastatin, it is important to understand its limitations:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShort duration:\u003c\/strong\u003e The treatment period was only 8 weeks. While this is sufficient to observe changes in lipid levels, it does not provide information about long-term efficacy, durability of the effect, or long-term safety.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurrogate endpoints:\u003c\/strong\u003e The study measured changes in blood lipid levels (triglycerides, non-HDL-C, etc.) rather than actual cardiovascular events like heart attacks or strokes. While lowering these lipids is strongly associated with reduced cardiovascular risk, the study did not directly demonstrate that the combination reduces heart attacks or strokes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSpecific population:\u003c\/strong\u003e The study was conducted in Korea with a specific population of high-risk patients (mainly those with diabetes and hypertension). The results may not be fully generalizable to other ethnic groups or to lower-risk populations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSpecific statin and omega-3 formulation:\u003c\/strong\u003e The study used atorvastatin 20 mg and a specific ATOMEGA formulation of omega-3 fatty acids. Results might differ with other statins, other doses, or other omega-3 formulations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited follow-up:\u003c\/strong\u003e The study did not track whether patients maintained their improvements over time or whether there were any post-treatment changes in lipid levels.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOlive oil placebo consideration:\u003c\/strong\u003e Although olive oil is a commonly used placebo in omega-3 trials, some research suggests that olive oil itself might have modest beneficial effects on lipids, which could slightly underestimate the true difference between treatment and control.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the findings of this study, here are practical recommendations for patients and their healthcare providers:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your full lipid profile.\u003c\/strong\u003e Achieving your LDL-C goal does not mean your lipid management is complete. Ask your doctor about your triglyceride and non-HDL-C levels, especially if you have diabetes, are overweight, or have other cardiovascular risk factors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider omega-3 supplements or prescription formulations.\u003c\/strong\u003e If your triglycerides remain above 200 mg\/dL despite statin therapy, ask your doctor whether adding omega-3 fatty acids at a dose of 4,000 mg\/day might be appropriate for you. This study shows that this combination can significantly improve your lipid profile without increasing side effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTake the full prescribed dose.\u003c\/strong\u003e The benefit demonstrated in this study was achieved with 4,000 mg of omega-3 fatty acids daily. Lower doses found in many over-the-counter fish oil supplements may not provide the same magnitude of benefit.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFollow lifestyle recommendations.\u003c\/strong\u003e Omega-3 fatty acids are a complement to—not a substitute for—a heart-healthy lifestyle. Continue to limit refined carbohydrates and saturated fats, exercise regularly, avoid smoking, and take all your prescribed medications as directed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTalk to your doctor about diabetes management.\u003c\/strong\u003e The majority of patients in this study had type 2 diabetes. If you have diabetes and high triglycerides despite statin therapy, you are exactly the type of patient who could benefit from this combination approach.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the secondary target.\u003c\/strong\u003e If your LDL-C is well controlled, ask your doctor what your non-HDL-C target should be and whether your current treatment is adequately addressing it. This study showed that adding omega-3 fatty acids to atorvastatin reduced non-HDL-C by 10.1%, a meaningful step toward reducing residual cardiovascular risk.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eAs always, it is essential to discuss any medication changes with your healthcare provider. Omega-3 fatty acids may interact with blood thinners and other medications, and the right dose and formulation should be determined based on your individual needs and medical history.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat did this trial find when omega-3 fatty acids were added to a statin?\u003c\/h3\u003e\n\u003cp\u003eIn a randomized, double-blind trial at 36 centers in Korea, adults with high triglycerides despite statin therapy took either 4,000 mg of omega-3 fatty acids plus 20 mg of atorvastatin or atorvastatin alone for 8 weeks. Triglycerides fell 29.8% with the combination versus a 3.6% rise with the statin alone.\u003c\/p\u003e\n\u003ch3\u003eWho was eligible to join this trial?\u003c\/h3\u003e\n\u003cp\u003eAdults aged 20 to 79 at high cardiovascular risk were screened. Those not on statins needed fasting triglycerides of at least 300 mg\/dL and LDL cholesterol between 100 and 160 mg\/dL. Those already on statins needed fasting triglycerides of at least 200 mg\/dL. After a run-in, participants needed residual triglycerides of at least 200 mg\/dL.\u003c\/p\u003e\n\u003ch3\u003eWhat does a 29.8% triglyceride reduction mean for a patient?\u003c\/h3\u003e\n\u003cp\u003eIn this trial, average triglycerides in the combination group fell from about 298.5 mg\/dL to about 210.6 mg\/dL over 8 weeks, a 29.8% drop. The statin-only group rose 3.6%. The difference between groups was highly statistically significant, meaning it was very unlikely to be due to chance.\u003c\/p\u003e\n\u003ch3\u003eHow many patients reached the triglyceride target below 200 mg\/dL?\u003c\/h3\u003e\n\u003cp\u003eAfter 8 weeks, 62.9% of patients taking omega-3 fatty acids plus atorvastatin reached the triglyceride target of below 200 mg\/dL, compared with only 22.3% of those taking atorvastatin alone. This difference was highly statistically significant. Reaching this target may help reduce future cardiovascular risk, though this trial did not measure heart attacks or strokes.\u003c\/p\u003e\n\u003ch3\u003eWere there more side effects when omega-3 fatty acids were added?\u003c\/h3\u003e\n\u003cp\u003eNo. In this 8-week trial, the incidence of adverse events did not differ between the group taking omega-3 fatty acids plus atorvastatin and the group taking atorvastatin alone. Researchers monitored laboratory parameters, electrocardiograms, vital signs, and physical examinations. This is consistent with the known safety profile of omega-3 fatty acids when added to statins.\u003c\/p\u003e\n\u003ch3\u003eDid adding omega-3 fatty acids interfere with the statin's cholesterol-lowering effect?\u003c\/h3\u003e\n\u003cp\u003eNo. LDL cholesterol changes did not differ significantly between groups (about –1.9% with the combination versus +6.5% with atorvastatin alone). This was expected and reassuring: adding omega-3 fatty acids did not reduce atorvastatin's cholesterol-lowering benefit, while other lipid measures such as non-HDL cholesterol improved.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this trial that patients should know?\u003c\/h3\u003e\n\u003cp\u003eThe trial lasted only 8 weeks and measured blood lipid levels, not heart attacks or strokes. It enrolled mainly Korean adults with high rates of diabetes and hypertension, used one specific statin dose and omega-3 formulation, and did not track long-term outcomes. Results may not apply to other groups, doses, or formulations.\u003c\/p\u003e\n\u003ch3\u003eMy triglycerides are still high on a statin — when should I get a second opinion about adding omega-3 fish oil?\u003c\/h3\u003e\n\u003cp\u003eWhen triglycerides remain at or above 200 mg\/dL despite statin therapy, that is residual hypertriglyceridemia, and a second opinion can help clarify whether adding omega-3 fatty acids at 4,000 mg daily is appropriate. In an 8-week trial, that combination lowered triglycerides by 29.8% and non-HDL-C by 10.1%, with 62.9% of patients reaching the target below 200 mg\/dL and no increase in side effects. A second opinion can also review your full lipid profile, diabetes management, and medication interactions before any change. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Ji Eun Jun, In-Kyung Jeong, Jae Myung Yu, Sung Rae Kim, In Kye Lee, Kyung-Ah Han, Sung Hee Choi, Soo-Kyung Kim, Hyeong Kyu Park, Ji-Oh Mok, Yong-ho Lee, Hyuk-Sang Kwon, So Hun Kim, Ho-Cheol Kang, Sang Ah Lee, Chang Beom Lee, Kyung Mook Choi, Sung-Ho Her, Won Yong Shin, Mi-Seung Shin, Hyo-Suk Ahn, Seung Ho Kang, Jin-Man Cho, Sang-Ho Jo, Tae-Joon Cha, Seok Yeon Kim, Kyung Heon Won, Dong-Bin Kim, Jae Hyuk Lee, Moon-Kyu Lee\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Diabetes \u0026amp; Metabolism Journal, 2020; Volume 44, pages 78–90. DOI: https:\/\/doi.org\/10.4093\/dmj.2018.0265\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTrial Registration:\u003c\/strong\u003e ClinicalTrials.gov (NCT03482180)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding and Ethics:\u003c\/strong\u003e The study protocol was approved by the Institutional Review Board or ethics committee at each participating center. All patients provided written informed consent. The study was conducted in accordance with the ethical standards of the relevant institutional and\/or national research committees and with the 1964 Helsinki Declaration and its later amendments.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. The original article is an open-access publication distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47699373129884,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/omega-3-fish-oil-added-to-statins-a-double-blind-trial-shows-significant-benefits-for-patients-with-residual-high-triglycerides","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}